Managing the overlap of asthma and chronic obstructive pulmonary disease

Knight, Anne

doi:10.18773/austprescr.2020.002

Cited by 8 publications

(7 citation statements)

References 22 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among patients who present with persistent airflow limitation, a proportion display the clinical features of both asthma and chronic obstructive pulmonary disease (COPD) [ 1 ]. While both are common chronic respiratory conditions, asthma and COPD arise via different pathophysiologic mechanisms [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Asthma and Chronic Obstructive Pulmonary Disease Overlap According to the Japanese Respiratory Society Diagnostic Criteria: The Prospective, Observational ACO Japan Cohort Study

et al. 2020

View full text Add to dashboard Cite

Introduction Patients with asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) present with chronic respiratory symptoms with features of both asthma and COPD. New ACO diagnostic criteria (2018) were suggested by the Japanese Respiratory Society (JRS). This prospective, multicenter, observational cohort study was conducted to investigate the proportion of patients who meet the JRS ACO diagnostic criteria among COPD patients in clinical practice. Methods This 2-year ongoing study enrolled consecutive outpatients aged ≥ 40 years with COPD who visited one of 27 Japanese centers at which the medical examinations/tests required for ACO diagnosis were routinely conducted. At registration, the proportion of ACO or non-ACO patients was determined using the JRS diagnostic criteria, and the characteristics of the two groups were compared using analysis of variance and chi-square test. Results Of 708 COPD patients analyzed at registration, 396 (55.9%) had the data necessary for ACO diagnosis to be conducted, and 312 (44.1%) were lacking these data. Of the 396 patients who had the data necessary for ACO diagnosis, 101 (25.5%) met the diagnostic criteria for ACO, and 295 (74.5%) did not (non-ACO patients). ACO patients were younger, had a greater rate of asthma based on a physician’s diagnosis, and used more medications, including inhaled corticosteroids ( p < 0.05), compared with non-ACO patients. Conclusions We have determined the proportion of patients with the data necessary to diagnose ACO using the JRS criteria, and the proportion of these who met the ACO criteria among the COPD population at the time of registration. Patients, including those lacking necessary examination/test data at registration, will continue to undergo follow-up to explore changes in their testing and ACO diagnostic status over time. Analyses of study data over 2 years will provide relevant information on the ACO symptoms, clinical course, and real-world treatment patterns. Trial registration ClinicalTrials.gov identifier, NCT03577795. Electronic supplementary material The online version of this article (10.1007/s12325-020-01573-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Asthma and Chronic Obstructive Pulmonary Disease Overlap According to the Japanese Respiratory Society Diagnostic Criteria: The Prospective, Observational ACO Japan Cohort Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The pretext for the use of MgSO 4 in COPD was its reported efficacy in asthma exacerbation 10 . Asthma and COPD represent overlapping clinical entities and they may co‐occur, although they are clinically distinct diseases 1 . There are several interventions that exert useful therapeutic effects for both asthma and COPD 1 .…”

Section: Magnesium (N = 39) Placebo (N = 38) Mean Difference (95% Ci)mentioning

confidence: 99%

“…C hronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. 1 Acute exacerbation of COPD (AECOPD) is a serious event during the natural course of the disease. 2 Despite many clinical trials on the management of AECOPD, treatment has not changed significantly during the past decades.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Adjunctive Effect of Intravenous Magnesium Sulfate in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Clinical Trial

Moradi

Pishbin

Habibzadeh

et al. 2020

Academic Emergency Medicine

View full text Add to dashboard Cite

“…Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of hospitalization, mortality, and increased consumption of medical expenses ( 1 – 2 ). In the natural course of disease, patients with COPD may experience a severe acute exacerbation of the disease.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Intravenous Magnesium Sulphate as an Adjuvant in the Treatment of Acute Exacerbations of COPD in the Emergency Department: A Double-Blind Randomized Clinical Trial

Jahanian¹,

Khatir²,

Ahidashti³

et al. 2021

Ethiop J Health Sci

View full text Add to dashboard Cite

BACKGROUND፡ Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are serious complications that often require immediate intervention in an emergency department (ED). The aim of this study was to investigate the effect of intravenous magnesium sulphate as an adjuvant in the treatment of AECOPD in the ED.METHODS: In a double-blind, randomized clinical trial, a total of 60 patients with AECOPD presenting to the ED of Imam Khomeini Hospital in Sari, Iran, were included. The study was conducted between September 2016 and February 2018. Eligible patients were randomly allocated into two groups of intervention and control. Patients in the intervention and control groups received intravenous infusion of magnesium sulfate (2 gr) or normal saline over 30 minutes, respectively. For all patients, Borgdyspnea score, forced expiratory volume in one second (FEV1) result and clinical variables of interest were evaluated before the beginning of the intervention, and also 45 minutes and 6 hours after the commencement of intervention.RESULTS: Regardless of time of evaluation, pulse rate (PR), respiratory rate (RR) and Borg score in intervention group was lower than control group. Also, FEV1 and SPO2 were greater in intervention group compared to control group. However, these differences were not statistically significant (between-subject differences or group effect) (p<0.001). The trends of FEV1, SPO2, PR, RR and Borg score were similar between two groups of study (no interaction effect; P>0.05).CONCLUSION: According to the results of this study, it seems that using intravenous magnesium sulfate has no significant effect on SPO2, FEV1, RR, and PR of patients with AECOPD who presented to ED.

show abstract

Managing the overlap of asthma and chronic obstructive pulmonary disease

Cited by 8 publications

References 22 publications

Asthma and Chronic Obstructive Pulmonary Disease Overlap According to the Japanese Respiratory Society Diagnostic Criteria: The Prospective, Observational ACO Japan Cohort Study

Asthma and Chronic Obstructive Pulmonary Disease Overlap According to the Japanese Respiratory Society Diagnostic Criteria: The Prospective, Observational ACO Japan Cohort Study

The Adjunctive Effect of Intravenous Magnesium Sulfate in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Clinical Trial

The Effect of Intravenous Magnesium Sulphate as an Adjuvant in the Treatment of Acute Exacerbations of COPD in the Emergency Department: A Double-Blind Randomized Clinical Trial

Contact Info

Product

Resources

About